We could hypothesize that masitinib could reduce depression symptoms in mastocytosis by two pathways: i. by blocking mediators secreted by mast cells involved in increasing permeability of the BBB and brain inflammation; ii. by reducing mast cells numbers in the thalamus or other structures of the limbic system through its direct effect on KIT and Lyn. Here, LYN is linked to depressive symptom measurement.